Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ
Abstract
:1. Introduction
2. Materials and Methods
2.1. Tissue Samples
2.2. Tissue Dissection and DNA Extraction
2.3. Detection of BRAF Mutations Using Real-Time PCR
2.4. Data Analysis
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Robins, P.; Perez, M.I. Understanding Melanoma; The Skin Cancer Foundation: New York, NY, USA, 1996. [Google Scholar]
- Barbarić, J.; Znaor, A. Incidence and mortality trends of melanoma in Croatia. Croat. Med. J. 2012, 53, 135–140. [Google Scholar] [CrossRef]
- Šitum, M. Melanom, Udžbenik i Atlas [Melanoma, Textbook and Atlas]; Medicinska Naklada: Zagreb, Croatia, 2016; p. 404. (In Croatian) [Google Scholar]
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In Volume 55: Solar and Ultraviolet Radiation; International Agency for Research on Cancer: Lyon, France, 1992. [Google Scholar]
- Elwood, J.M.; Jopson, J. Melanoma and sun exposure: An overview of published studies. Int. J. Cancer 1997, 73, 198–203. [Google Scholar] [CrossRef]
- Ting, W.; Schultz, K.; Cac, N.N.; Peterson, M.; Walling, H.W. Tanning bed exposure increases the risk of malignant melanoma. Int. J. Dermatol. 2007, 46, 1253–1257. [Google Scholar] [CrossRef]
- Nelson, A.A.; Tsao, H. Melanoma and genetics. Clin. Dermatol. 2009, 27, 46–52. [Google Scholar] [CrossRef] [PubMed]
- Schadendorf, D.; Fisher, D.E.; Garbe, C.; Gershenwald, J.E.; Grob, J.J.; Halpern, A.; Herlyn, M.; Marchetti, M.A.; McArthur, G.; Ribas, A.; et al. Melanoma. Nat. Rev. Dis. Prim. 2015, 1, 15003. [Google Scholar] [CrossRef] [PubMed]
- Azoury, S.C.; Lange, J.R. Epidemiology, risk factors, prevention and early detection of melanoma. Surg. Clin. N. Am. 2014, 94, 945–962. [Google Scholar] [CrossRef]
- Vučić, M.; Tomas, D.; Krušlin, B. Patohistološka slika melanoma kože [Pathohysiology of skin melanoma]. In Melanom, Udžbenik i Atlas [Melanoma, Textbook and Atlas]; Šitum, M., Ed.; Medicinska Naklada: Zagreb, Croatia, 2016; pp. 2167–2179. (In Croatian) [Google Scholar]
- Shain, A.H.; Bastian, B.C. From melanocytes to melanomas. Nat. Rev. Cancer 2016, 16, 345–358. [Google Scholar] [CrossRef]
- Bastian, B.C. The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu. Rev. Pathol. Mech. Dis. 2014, 9, 239–271. [Google Scholar] [CrossRef]
- Goldstein, A.M.; Margaret, A.T. Dysplastic nevi and melanoma. Cancer Epidemiol. Biomark. Prev. 2013, 22, 528–532. [Google Scholar] [CrossRef]
- Junqueira, L.C.; Carneiro, J.; Kelley, R.O. Basic Histology. In LANGE Medical Book; Appleton & Lange: New York, NY, USA, 1998. [Google Scholar]
- Smoller, B.R. Histologic criteria for diagnosis primary cutaneous malingnant melanoma. Mod. Pathol. 2006, 19, S34–S40. [Google Scholar] [CrossRef]
- Tschandl, P.; Berghoff, A.S.; Preusser, M.; Burgstaller-Muehlbacher, S.; Pehamberger, H.; Okamoto, I.; Kittler, H. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS ONE 2013, 8, e69639. [Google Scholar] [CrossRef] [PubMed]
- Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [Google Scholar] [CrossRef]
- Roskoski, R., Jr. RAF protein-serine/threonine kinases: Structure and function. Biochem. Biophys. Res. Commun. 2010, 399, 313–317. [Google Scholar] [CrossRef]
- Lopez-Rios, F.; Angulo, B.; Gomez, B.; Mair, D.; Martinez, R.; Conde, E.; Shieh, F.; Vaks, J.; Langland, R.; Lawrence, H.J.; et al. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: Pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS ONE 2013, 8, e53733. [Google Scholar] [CrossRef] [PubMed]
- Shinozaki, M.; Fujimoto, A.; Morton, D.L.; Hoon, D.S.B. Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas. Clin. Cancer Res. 2004, 10, 1753–1757. [Google Scholar] [CrossRef]
- Michaloglou, C.; Vredeveld, L.C.W.; Mooi, W.J.; Peeper, D.S. BRAFE600 in benign and malignant human tumors. Oncogene 2008, 27, 877–895. [Google Scholar] [CrossRef] [PubMed]
- Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 2012, 11, 873–886. [Google Scholar] [CrossRef]
- Sullivan, R.J.; Flatherty, K.T. BRAF in melanoma: Pathogenesis, diagnosis, inhibition and resistance. J. Skin Cancer 2011, 2011, 423239. [Google Scholar] [CrossRef]
- Gandini, S.; Sera, F.; Cattaruzza, M.S.; Paquini, P.; Picconi, O.; Boyle, P. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur. J. Cancer 2005, 41, 45–60. [Google Scholar] [CrossRef]
- Tsao, H.; Chin, H.; Garraway, L.A.; Fisher, D.E. Melanoma: From mutations to medicine. Genes Dev. 2012, 26, 1131–1155. [Google Scholar] [CrossRef]
- Pollock, P.M.; Harper, U.L.; Hansen, K.S.; Yudt, L.M.; Stark, M.; Robbins, C.M. High frequency of BRAF mutations in nevi. Nat. Genet. 2003, 33, 19–20. [Google Scholar] [CrossRef] [PubMed]
- Bauer, J.; Büttner, P.; Murali, R.; Okamoto, I.; Kolaitis, N.A.; Landi, M.T.; Scolyer, R.A.; Bastian, B.C. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site. Pigm. Cell Melanoma Res. 2011, 24, 345–351. [Google Scholar] [CrossRef] [PubMed]
- Menzies, A.M.; Haydu, L.E.; Visintin, L.; Carlino, M.S.; Howle, J.R.; Thompson, J.F.; Kefford, R.F.; Scolyer, R.A.; Long, G.V. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012, 18, 3242–3249. [Google Scholar] [CrossRef] [PubMed]
- Balch, C.M.; Houghton, A.N.; Sober, A.J.; Soong, S.J. Cutaneous Melanoma, 4th ed.; Quality Medical Publishing, Inc.: St. Louis, MO, USA, 2003. [Google Scholar]
- Ivkić, M.; Bedeković, V. Melanom glave i vrata. In Melanom, Udžbenik i Atlas [Melanoma, Textbook and Atlas]; Šitum, M., Ed.; Medicinska Naklada: Zagreb, Croatia, 2016; pp. 84–121. (In Croatian) [Google Scholar]
- Nikolaou, V.; Stratigos, A.J. Emerging trends in epidemiology of melanoma. Br. J. Dermatol. 2014, 170, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Curtin, J.A.; Fridlyand, J.; Kageshita, T.; Patel, H.N.; Busam, K.J.; Kutzner, H.; Cho, K.H.; Aiba, S.; Bröcker, E.B.; LeBoit, P.E.; et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353, 2135–2147. [Google Scholar] [CrossRef] [PubMed]
- Mackiewicz-Wysocka, M.; Czerwińska, P.; Filas, V.; Bogajewska, E.; Kubicka, A.; Przybyła, A.; Dondajewska, E.; Kolenda, T.; Marszałek, A.; Mackiewicz, A. Oncogenic BRAF Mutations and P16 Expression in Melanocytic Nevi and Melanoma in the Polish Population. Postepy Dermatol. Alergol. 2017, 34, 490–498. [Google Scholar] [CrossRef] [PubMed]
Diagnosis | BRAF Mutation | Total | |
---|---|---|---|
No | Yes | ||
ND | 44 (41.5%) | 62 (58.5%) | 106 |
MIS | 16 (39.0%) | 25 (60.9%) | 41 |
LM | 27 (96.4%) | 1 (3.6%) | 28 |
Total | 87 (49.7%) | 88 (50.3%) | 175 |
Localization | BRAF Mutation | Total | |
---|---|---|---|
No | Yes | ||
Trunk | 45 (38.5%) | 72 (61.5%) | 117 |
Head | 22 (84.6%) | 4 (15.4%) | 26 |
Upper limbs | 7 (50.0%) | 7 (50%) | 14 |
Lower limbs | 13 (72.2%) | 5 (27.8%) | 18 |
Total | 87 (49.7%) | 88 (50.3%) | 175 |
Previous Diagnosis | BRAF Mutation | Total | |
---|---|---|---|
No | Yes | ||
No melanoma | 72 (48.0%) | 78 (52.0%) | 150 |
With melanoma | 15 (60.0%) | 10 (40%) | 25 |
Total | 87 (49.7%) | 88 (50.3%) | 175 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Prkačin, I.; Šamija, I.; Filipović, N.; Vucić, M.; Vučić, M.; Ferara, N.; Šitum, M. Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ. J. Clin. Med. 2024, 13, 4799. https://doi.org/10.3390/jcm13164799
Prkačin I, Šamija I, Filipović N, Vucić M, Vučić M, Ferara N, Šitum M. Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ. Journal of Clinical Medicine. 2024; 13(16):4799. https://doi.org/10.3390/jcm13164799
Chicago/Turabian StylePrkačin, Ivana, Ivan Šamija, Nika Filipović, Matej Vucić, Majda Vučić, Nikola Ferara, and Mirna Šitum. 2024. "Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ" Journal of Clinical Medicine 13, no. 16: 4799. https://doi.org/10.3390/jcm13164799